Nondopaminergic symptomatic therapies for Parkinson's disease: turn on or turn off?
Feigin
Andrew
A
D058917:Adenosine A2 Receptor Antagonists; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D009043:Motor Activity / Q000187:drug effects; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000378:metabolism / Q000628:therapy*; D011687:Purines / Q000627:therapeutic use*; D011788:Quality of Life
D058917:Adenosine A2 Receptor Antagonists; D018680:Cholinergic Antagonists; D018696:Neuroprotective Agents; D011687:Purines; C111599:istradefylline; D004298:Dopamine